Intravitreal Triamcinolone Acetonide for Macular Edema Associated With Diabetic Retinopathy and Venous Occlusive Disease

Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years

“…1 It is interesting to note that IVTA is being used as a primary treatment for diabetic macular oedema 4,5 and that The National Eye Institute, US, is performing a randomised controlled trial comparing macular laser treatment vs IVTA. 15 This will inevitably lead to almost every treated eye developing sight-threatening cataract.…”

Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years

“…1 It is interesting to note that IVTA is being used as a primary treatment for diabetic macular oedema 4,5 and that The National Eye Institute, US, is performing a randomised controlled trial comparing macular laser treatment vs IVTA. 15 This will inevitably lead to almost every treated eye developing sight-threatening cataract.…”

A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Standard Care to Treat Vision Loss Associated With Macular Edema Secondary to Branch Retinal Vein Occlusion

“…The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study, sponsored by the National Eye Institute, is a clinical trial designed to compare 1-mg and 4-mg doses of intravitreal triamcinolone with standard care for vision loss associated with macular edema secondary to per-fused central retinal vein occlusion (CRVO) and BRVO 35,36. This article describes findings from the SCORE-BRVO trial.…”

A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein Occlusion

“…The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study, sponsored by the National Eye Institute, is a clinical trial designed to compare 1-mg and 4-mg doses of intravitreal triamcinolone with standard care for treatment of vision loss associated with macular edema secondary to perfused CRVO and branch retinal vein occlusion (BRVO) 29,30. This article describes findings from the SCORE-CRVO trial.…”

Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years

“…1 It is interesting to note that IVTA is being used as a primary treatment for diabetic macular oedema 4,5 and that The National Eye Institute, US, is performing a randomised controlled trial comparing macular laser treatment vs IVTA. 15 This will inevitably lead to almost every treated eye developing sight-threatening cataract.…”

A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Standard Care to Treat Vision Loss Associated With Macular Edema Secondary to Branch Retinal Vein Occlusion

“…The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study, sponsored by the National Eye Institute, is a clinical trial designed to compare 1-mg and 4-mg doses of intravitreal triamcinolone with standard care for vision loss associated with macular edema secondary to per-fused central retinal vein occlusion (CRVO) and BRVO 35,36. This article describes findings from the SCORE-BRVO trial.…”

A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein Occlusion

“…The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study, sponsored by the National Eye Institute, is a clinical trial designed to compare 1-mg and 4-mg doses of intravitreal triamcinolone with standard care for treatment of vision loss associated with macular edema secondary to perfused CRVO and branch retinal vein occlusion (BRVO) 29,30. This article describes findings from the SCORE-CRVO trial.…”

Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years

“…1 It is interesting to note that IVTA is being used as a primary treatment for diabetic macular oedema 4,5 and that The National Eye Institute, US, is performing a randomised controlled trial comparing macular laser treatment vs IVTA. 15 This will inevitably lead to almost every treated eye developing sight-threatening cataract.…”

A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Standard Care to Treat Vision Loss Associated With Macular Edema Secondary to Branch Retinal Vein Occlusion

“…The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study, sponsored by the National Eye Institute, is a clinical trial designed to compare 1-mg and 4-mg doses of intravitreal triamcinolone with standard care for vision loss associated with macular edema secondary to per-fused central retinal vein occlusion (CRVO) and BRVO 35,36. This article describes findings from the SCORE-BRVO trial.…”

A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein Occlusion

“…The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study, sponsored by the National Eye Institute, is a clinical trial designed to compare 1-mg and 4-mg doses of intravitreal triamcinolone with standard care for treatment of vision loss associated with macular edema secondary to perfused CRVO and branch retinal vein occlusion (BRVO) 29,30. This article describes findings from the SCORE-CRVO trial.…”